Observational Study on the Application of High-Flow Therapy After Percutaneous Transfemoral Aortic Valve Replacement
Sponsored by Drägerwerk AG & Co. KGaA
About this trial
Last updated 4 years ago
Study ID
TAVI-STAR
Status
Completed
Type
Observational
Placebo
No
Accepting
18+ Years
All
Not accepting
Healthy Volunteers
Trial Timing
Ended 4 years ago
What is this trial about?
Percutaneous catheter-assisted valve replacement in aortic position (TAVI) for patients
with high perioperative risk has become a standard method in recent years. In addition to
the detection of bleeding and cardiac rhythm complications, follow-up care is mainly
focused on the monitoring of respiratory parameters after an operation under intubation
anesthesia or deep analgosedation. In addition to normal oxygen therapy, non-invasive
ventilation and, in case of weaning failure, renewed tracheal intubation in the first 24
h after TAVI have been considered. High flow oxygen therapy (HFOT) now provides a good
opportunity to treat patients with a warmed and humidified air-oxygen mixture and to
independently control the oxygen content in the inhaled air and the flow in the
pharyngeal area.
The aim of the Study is to investigate the Change in oxygenation after high-flow oxygen
therapy as a measure of weaning success in postinterventional patients after TAVI.
What are the participation requirements?
Inclusion Criteria
- High-flow oxygen therapy after TAVI
Exclusion Criteria
- patients without consent
- age < 18 years